Dabur India nears 52-week high on strong volume growth in September qtr

The stock has rallied 5% in two trading days, quoting close to its 52-week high level of Rs 535 touched on October 6, 2020

Dabur India reported a strong growth performance in Q2FY21
Dabur India reported a strong growth performance in Q2FY21
SI Reporter Mumbai
2 min read Last Updated : Nov 04 2020 | 12:56 PM IST
Shares of Dabur India were up 3 per cent to Rs 530 on the BSE in the intra-day trade on Wednesday, gaining 5 per cent in the past two trading days, after the FMCG major reported a strong 16.8 per cent year-on-year volume growth in September quarter (Q2FY21). Stock of the personal products company was trading close to its 52-week high level of Rs 535, touched on October 6, 2020.

Dabur India reported a strong growth performance in Q2FY21 backed by sustained efforts in driving demand for its Ayurvedic Healthcare, Hygiene and Nutrition products, coupled with strong innovation to meet the emerging consumer needs in the wake of the Covid-19 pandemic.

In Q2FY21, the company's consolidated revenue grew 13.7 per cent YoY at Rs 2,516 crore, highest in the last couple of quarters. Consolidated net profit, meanwhile, rose 19.5 per cent at Rs 482 crore on YoY basis. Operating EBITDA (earnings before interest, taxes, depreciation, and amortisation) margins expanded 50 basis points to 22.6 per cent.

The management said favourable monsoon and enhanced stimulus announced by the government as part of its overall thrust on boosting rural economy is expected to further drive rural demand in the coming months.

"With strong tailwind from health and immunity products, Dabur India got the new structural growth levers. We believe the company would continue to witness strong growth in the medium term from these trends. Moreover, benign commodity cost and savings programme leaves enough scope to increase margins over the long term," ICICI Securities said in result update.

Growth outlook, analysts at Emkay Global Financial Services say, has improved on the back of strong traction in healthcare and improving growth across Home and Personal Care (HPC) and increased aggression in portfolio and distribution expansion. "However, valuations at 39x FY23 and limited upsides to earnings keep us neutral/OW in EAP on the stock," the brokerage said with target price of Rs 530 per share.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Dabur IndiaBuzzing stocksMarkets

Next Story